Aflac Incorporated

- Currently, there are no real plans to increase leverage or raise new debt. - The company holds significant capital and liquidity at the holding company to deploy into operations and back to shareholders. - External reinsurance strategies will consume some capital but are expected to be additive and not alter capital deployment to shareholders. - Capital management is flexible and tactical, with strong capital ratios and liquidity ($3.4 billion unencumbered liquidity). - Adjusted leverage stands at 21.2%, within the target range of 20%-25%, influenced by yen-dollar exchange rates as part of a hedging program. - There is ongoing capital deployment through share repurchases ($1 billion) and dividends ($315 million) in Q1. - No mention of equity fundraising or plans for public equity issuance at this time.

- Aflac is investing in improving and enhancing its enrollment process to ease onboarding for new agents, helping them sell quickly and be productive early. - The company is investing in innovative products and technology, especially focused on group product offerings catering to smaller employee groups. - External reinsurance deals are pursued as an add-on strategy to grow business and earnings power with good IRRs, diversify earnings streams, and risk profiles without materially consuming capital or affecting shareholder returns. - No current plans to increase leverage; however, there is flexibility to deploy significant capital and liquidity for operations, shareholder returns, or strategic investments like reinsurance deals. - The recent reinsurance transaction with Japan Post Insurance marks a strategic expansion of their reinsurance franchise targeting the Japan market. - Overall, investments focus on methodical growth, evolution rather than revolution, emphasizing capital efficiency and maintaining strong capital ratios.

- Japan sales target for 2026 is around JPY 80 billion, slightly higher than 2025’s JPY 74 billion (Dan Amos, Page 12). - Japan's new cancer product and medical product sales showed strong growth in Q1, encouraging outlook for Aflac Japan (Virgil Miller, Page 12). - Aflac Japan expects sales of cancer insurance products in 2026 to be equivalent to 2025, supported by concurrent selling of multiple products (Koichiro Yoshizumi, Page 6). - Japan’s earned premium growth is currently negative 1-2%; flat to modest growth expected when sales reach about JPY 90 billion to offset lapsation (Page 9). - U.S. group business sales up 12.4% in Q1; core agent business flat to slightly down but investments underway to boost agent recruitment and productivity (Virgil Miller, Page 8). - U.S. sales increased 2.9% year-over-year in Q1 with strong premium persistency and net earned premium growth of 3.5% (Page 2).

- Daniel Amos expects Japan sales to be closer to JPY 80 billion in 2026, higher than 2025's JPY 74 billion, indicating growth ambition. - Earned premium growth in Japan is expected to hover around negative 1% to 2% for the full year, with a midterm strategy focused on new business growth to end stagnation. - U.S. segment shows strong sales growth, with a 2.9% YoY increase and stable benefit ratio guidance of 42%-52% for the full year. - Adjusted Q1 earnings per diluted share increased 6.6% YoY to $1.77 (excluding FX effects), with adjusted ROE at 12.8%. - External reinsurance deals are seen as additive strategies to diversify earnings and grow business with good IRRs, not expected to significantly consume capital or alter shareholder returns. - Despite market challenges, management expects solid profitability and sustained capital deployment to shareholders through dividends and share repurchases.

- Daniel Amos indicated a target sales figure of around JPY 80 billion for Japan in 2026, higher than 2025's JPY 74 billion, suggesting an expectation of increased orderbook/sales. - Max Broden confirmed JPY 90 billion in sales is needed for flat premium growth in Japan, highlighting that current levels are below that but expected to improve. - Virgil Miller noted strong sales growth in new cancer and medical products in Japan Q1, contributing positively to orderbook. - Aflac Japan has introduced multiple products being sold concurrently, which supports a healthy sales pipeline. - The company maintains a focus on continuing to grow the business methodically, signaling stable pending orders. - No explicit numeric figures on current orderbook or pending orders were disclosed; however, the emphasis on maintaining or increasing sales around JPY 80-90 billion indicates a robust order pipeline.